Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06475807 · ClinicalTrials.gov registry record · NA

Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors

A NA study of Cancer, sponsored by University of Pittsburgh.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT06475807: Recruiting NA study of Cancer, sponsored by University of Pittsburgh.

NCT06475807 is a NA study of Cancer that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 60 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06475807, a NA study of Cancer, is actively recruiting participants, sponsored by University of Pittsburgh.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This pilot trial will study the potential impact of two distinct dietary interventions with sequential use of high-fermented foods and high-fiber supplements on the gut microbiome and antitumor immunity in patients with melanoma and non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors. The trial aims to understand how dietary changes affect the composition and function of the gut microbiome, together with immunological and metabolomic markers in serum in patients with melanoma and NSCLC who are undergoing standard-of-care treatment with a PD-1/PD-L1 Inhibitors (neoadjuvant, adjuvant or consolidation)

Primary Outcome

Changes in gut microbiome diversity and function, evaluated with metagenomics, identify differentially abundant taxa and assess all genes in all organisms present in each fecal microbiota sample in pre- vs. post- each dietary using PERMANOVA. This will be measured as change of cell frequency and calculated as percentage change.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT High-fermented food
  • DIETARY_SUPPLEMENT High fiber supplementation

Study Locations (1)

Pennsylvania

  • UPMC Hillman Cancer Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-07-17
Est. Completion 2027-06
Phase NA
University of Pittsburgh

1,238 total trials

What NCT06475807 shows while recruiting

NCT06475807 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which High-fermented food is the first listed.

NCT06475807 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06475807 about?

NCT06475807 is a clinical study titled "Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors". This pilot trial will study the potential impact of two distinct dietary interventions with sequential use of high-fermented foods and high-fiber supplements on the gut microbiome and antitumor immunity in patients with melanoma and non-small cell lung cancer (NSCLC) treated with immune checkpoint i...

What is the current status of trial NCT06475807?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-07-17. Estimated completion is 2027-06.

What conditions does trial NCT06475807 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT06475807?

The interventions under investigation include: High-fermented food (DIETARY_SUPPLEMENT), High fiber supplementation (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06475807?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06475807 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06475807's enrollment target sits among peer trials

60 393rd of 615 higher than 208 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06475807, the US trial registry maintained by the National Library of Medicine. NCT06475807 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.